Organizations Filed Purposes:
MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. ("MTF- OR THE "FOUNDATION") IS DEDICATED TO PROVIDING QUALITY ALLOGRAFT TISSUE FOR TRANSPLANTATION THROUGH A COMMITMENT TO EXCELLENCE IN EDUCATION, RESEARCH, RECOVERY, AND CARE FOR RECIPIENTS, DONORS AND THEIR FAMILIES. MTF CONTINUES TO PROMOTE THE HEALTH AND WELFARE OF THE GENERAL PUBLIC BY (1) MAXIMIZING THE AVAILABILITY OF HIGH QUALITY HUMAN TISSUE INCLUDING BONE, DERMAL AND BIRTH TISSUE; 2) SUPPORTING MEDICAL, SCIENTIFIC AND OTHER EDUCATIONAL RESEARCH WITH RESPECT TO TISSUE DONATION, RECOVERY AND TRANSPLANTATION; AND(3) EDUCATING THE GENERAL PUBLIC WITH RESPECT TO THE IMPORTANCE AND BENEFITS OF TISSUE DONATION AND TRANSPLANTATION. THE MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. WAS INCORPORATED ON JANUARY 30, 1987, AS A DISTRICT OF COLUMBIA NON- PROFIT MEMBERSHIP ORGANIZATION AND IS A 501(C)(3)ORGANIZATION. THERE IS A CRITICAL NEED FOR MUSCULOSKELETAL, CARDIOVASCULAR, SKIN, BIRTH AND OCULAR TISSUE FOR TRANSPLANTATION. IN ORDER TO ACCOMPLI
MTF IS A NONPROFIT ORG. THAT SAVES AND HEALS LIVES BY HONORING DONATED GIFTS AND SERVING PATIENTS, WE COLLABORATE WITH THE MEDICAL, SCIENTIFIC, AS WELL AS ORGAN AND TISSUE DONATION COMMUNITIES. CONTINUED ON SCHEDULE O.
MTF PROVIDES ALLOGRAFT TISSUES TO THE MEDICAL COMMUNITY. SINCE ITS INCEPTION IN 1987, MTF, THE NATION'S LEADING TISSUE BANK, HAS RECEIVED TISSUE DONATIONS FROM OVER 140,000 DONORS. IN 2019, MTF RECOVERED TISSUE FROM OVER 5,500 DONORS FOR USE IN MUSCULOSKELETAL AND BONE ALLOGRAFT APPLICATIONS, OVER 5,300 DONORS FOR USE IN BURN, GENERAL, AND PLASTIC SURGERY APPLICATIONS, OVER 1,200 DONORS FOR USE IN WOUNDCARE APPLICATIONS AND OVER 900 DONORS FOR ORGANS AND TISSUES FOR RESEARCH. OVERALL, MTF DISTRIBUTED MORE THAN 490,000 UNITS OF ALLOGRAFT TISSUE DURING 2019. MTF CONTINUED TO DONATE ALLOGRAFT TISSUES FOR RESEARCH, MEDICAL, AND EDUCATIONAL PURPOSES. IN COLLABORATION WITH SURGEONS, MTF CONTINUES TO DEVELOP INNOVATIVE TISSUE FORMS, FOCUSED ON SOLVING REAL-WORLD, CLINICAL PROBLEMS. MTF HAS ALSO CONTINUED ITS EFFORTS TO PROVIDE SPECIAL RESEARCH TISSUE FOR RESEARCH PERFORMED BY MEMBERS OF THE ARMED FORCES INSTITUTE OF REGENERATIVE MEDICINE (AFIRM), AN ORGANIZATION DEDICATED TO DEVELOPING MEDICAL THERAPIES FOR WOUNDED SOLDIERS. IN DECEMBER OF 2019, MTF PROVIDED NEARLY 500 LIFE SAVING, SKIN-FOR-BURN GRAFTS TO ASSIST IN THE INTERNATIONAL EFFORT TO TREAT VICTIMS INJURED IN THE VOLCANO ERUPTION IN NEW ZEALAND. THIS EFFORT WAS ACCOMPLISHED THROUGH COLLABORATION WITH THE DONOR TISSUE BANK OF VICTORIA IN AUSTRALIA. IN 2019, MTF CONTINUED TO INCREASE TISSUE UTILIZATION AND PLACEMENT OF TISSUE FORMS IN THE ORTHOPEDIC, PLASTIC AND RECONSTRUCTIVE SURGERY, AND WOUND CARE MARKETS. IN THE ORTHOPEDICS MARKET, MTF LAUNCHED QUICKGRAFT, A PRE-SUTURED TENDON FOR USE IN SPORTS MEDICINE PROCEDURES. THIS TECHNOLOGY ALLOWS MTF AND SURGEON PARTNERS TO HONOR THE DONATED GIFT BY INCREASING THE PREDICTABILITY OF SURGICAL PROCEDURES FOR THE PATIENT ALL THE WHILE USING TENDONS THAT WERE NOT PREVIOUSLY OF HIGH DEMAND. MTF ALSO CONTINUED TO INCREASE ITS UTILITY OF THE MOPS OSTEOCHONDRAL PRESERVATION TECHNOLOGY, PROVIDING HIGHER QUALITY TISSUE FOR DOCTORS AND PATIENTS, WHILE REDUCING THE TIME TO MATCH A TISSUE DONATION TO A RECIPIENT. MTF ALSO BEGAN TO DISTRIBUTE CC+, A CORTICAL-CANCELLOUS BONE VOID FILLER THAT ALLOWS THE DONATED TISSUE TO REACH MORE RECIPIENTS WITHOUT COMPROMISING QUALITY OR EFFECTIVENESS. FURTHERMORE, MTF LAUNCHED A NEW CORTICAL FIBER BASED BONE VOID FILLER, FIBER FUSE WHICH POSSESSES OSTEO-INDUCTIVE, OSTEO-CONDUCTIVE POTENTIAL AND EXCELLENT HANDLING PROPERTIES. IN PLASTIC AND RECONSTRUCTIVE SURGERY (PRS), MTF LAUCHED FLEXHD PRE, AN INNOVATIVE TISSUE FORM, DESIGNED TO ALLOW SURGEONS GREATER OPTIONS FOR BREAST RECONSTRUCTION PROCEDURES FOLLOWING MASTECTOMY. THE MTF PRS DIVISION ALSO SAW AN INCREASED USE OF RENUVA, AN OFF-THE-SHELF ADIPOSE MATRIX, FOR RECONSTRUCTION AND TREATMENT OF SMALL VOLUME DEFECTS WHERE HOST FAT HAS EITHER DECREASED OR BEEN DEGRADED OR LOST DUE TO TRAUMA OR DISEASE. MTF'S WOUND CARE DIVISION DEVELOPED AND LAUNCHED SOMAGEN, A TISSUE FORM DESIGNED TO INCREASE WOUND COVERAGE AREA, WHILE STILL DECREASING THE TIME TO CLOSURE. ADDITIONALLY, LENEVA AN OFF-THE-SHELF SOFT TISSUE ADIPOSE MATRIX WAS LAUNCHED TO TREAT FAT PAD ATROHPE AND AVOID THE DEVELOPMENT OF ULCERS. MTF ALSO CONTINUED EXPANDING THE DISTRIBUTION OF ITS WOUND CARE PORTFOLIO TO MORE RECIPIENTS IN THE VA AND PUBLIC HOSPITALS THROUGHOUT THE YEAR. THIS WAS ACHIEVED THROUGH THE PUBLICATION OF MORE POSITIVE, PEER REVIEWED, CLINICAL OUTCOMES PAPERS COUPLED WITH THE ACCEPTANCE OF THE MTF WOUNCE CARE TISSUE FORMS BY MORE THIRD PARTY INSURANCE PROVIDERS AS MEDICALLY NECESSARY. MTF CONTINUED TO EXPAND ITS CLINICAL STUDY PORTFOLIO, INCREASING ITS COMPENDIUM OF CLINICAL DATA FOR EXPANDED REIMBURSEMENT IN WOUND CARE AND BREAST RECONSTRUCTION. MTF CONTINUED ITS PROSPECTIVE RANDOMIZED CLINICAL TRIAL FOR FLEXHD PLIABLE ACELLULAR DERMAL MATRIX USED FOR BREAST RECONSTRUCTION FOLLOWING MASTECTOMY. IN THE WOUND CARE MARKET, CLINICAL STUDIES AND RESEARCH DATA HAVE PROVIDED THE INFORMATION FOR MTF TO ATTAIN COVERAGE FOR APPROXIMATELY 73% OF ALL COVERED AMERICAN LIVES IN 2019. MTF CONTINUED ITS SUPPORT OF THE AMERICAN SOCIETY OF PLASTIC SURGEONS (ASPS) AND THE PLASTIC SURGERY FOUNDATION (PSF) WHICH PROVIDES OPPORTUNITES FOR SURGEONS TO PERFORM ALLOGRAFT BASED RESEARCH TO ADVANCE THE SCIENCE OF ALLOGARFT USE IN PLASTIC/RECONSTRUCTIVE PROCEDURES. MTF ALSO REMAINS COMMITTED TO SUPPORTING BREAST RECONSTRUCTION AWARENESS (BRA) DAY EACH YEAR AND INCLUDES EDUCATION FOR BOTH PATIENTS AND SURGEONS ON THE OPTIONS AVAILABLE TODAY FOR WOMEN, HELPING TO ENSURE SURVIVORS' RIGHTS TO MAKE AN INFORMED DECISION. MTF ALSO CONTINUED ITS FINANCIAL PLEDGE OF (1M OVER FIVE YEARS) TO SUPPORT BIOLOGIC RESEARCH THROUGH THE PLASTIC SURGERY FOUNDATION (PSF). MTF'S MISSION IS TO SAVE AND HEAL LIVES BY HONORING THE DONATED GIFT, SERVING PATIENTS AND ADVANCING SCIENCE. FOR INDIVIDUAL STORIES ABOUT DONOR FAMILIES, PLEASE VISIT MTF BIOLOGICS WEBSITE AT HTTPS://WWW.MTFBIOLOGICS.ORG/WHO-WE-SERVE/DONORS- COMMUNITY/DONORS-FAMILIES. STORIES ABOUT RECIPIENTS ARE ALSO AVAILABLE ON THE WEBSITE AT HTTPS://WWW.MTFBIOLOGICS.ORG/WHO-WE-SERVE/DONORS- COMMUNITY/RECIPIENTS AND ON THE YOUTUBE CHANNEL AT HTTPS://WWW.YOUTUBE.COM/USER/THEMTF1.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Bruce W Stroever | PRES - ENDED | 0 | $756,938 |
| Beth Brett | SURGICAL CON | 50 | $672,034 |
| Joseph A Yaccarino | PRESIDENT/CE | 60 | $643,159 |
| Floyd Vaughan | SURGICAL CON | 50 | $533,875 |
| Michael J Kawas | TREASURER/CF | 60 | $529,212 |
| Elyce Pincus | WOUNDCARE TR | 50 | $439,859 |
| Thomas C Shaffer | EXEC VP SALE | 60 | $432,627 |
| Martha Anderson | EXEC VP DONO | 60 | $432,589 |
| Jodie Crabil | SURGICAL CON | 50 | $429,349 |
| John Zook | VP ORTHOPEDI | 50 | $410,486 |
| Jennifer Birmingham | SECRETARY/GE | 60 | $374,198 |
| Michael Oleck | EXEC VP OPS | 60 | $359,634 |
| Marc Long | EXEC R & D | 60 | $320,167 |
| William W Tomford Md | DIRECTOR | 4 | $50,000 |
| Joseph Zuckerman Md | DIRECTOR | 1 | $17,000 |
| Dan M Spengler Md | DIRECTOR | 1 | $16,000 |
| Donald Hackbarth Md | DIRECTOR | 1 | $16,000 |
| Deryk Jones Md | DIRECTOR | 1 | $15,000 |
| David Kulber Md | DIRECTOR | 1 | $13,000 |
| Joseph A Buckwalter Md | DIRECTOR | 1 | $12,000 |
| Alan Milanazzo | DIRECTOR | 1 | $11,000 |
| Joseph Roth | DIRECTOR | 1 | $7,000 |
| Allan Gross Md | DIRECTOR | 1 | $4,000 |
| Gerald Finerman Md | NON-VOTING D | 1 | $0 |
| Victor Frankel Mdphd | NON-VOTING D | 1 | $0 |
| Tracy Schmidt | DIRECTOR | 1 | $0 |
| Mark Bolander Md | DIRECTOR | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202043219349306144_public.xml